In the inaugural issue, we have critically examined the functioning of Indias vast clinical trials industry. Given the way vaccines, certain drugs and treatment protocols have been fast-tracked by the regulatory authorities in order to tackle the serious health crisis resulting from the Covid-19 pandemic, several moral and ethical questions arise that impact the lives and safety of millions of patients. for Long, experts have been demanding greater transparency and accountability from Indian drug regulators. Besides that, it also covers in-depth reporting on the CSR activities and the impact of Covid on the social sector.